Boardroom Alpha
Start trial
10-K primary document
XENE · Annual Report (Form 10-K) · Filed February 26, 2026

Xenon Pharmaceuticals Inc — 10-K exhibit

xene-ex23_2.htm
Xenon Pharmaceuticals Inc on Boardroom Alpha
EX-23.2

 

 

Exhibit 23.2

Consent of Independent Registered Public Accounting Firm

The Board of Directors
Xenon Pharmaceuticals Inc.

We consent to the use of our report dated February 27, 2025 on the consolidated financial statements of Xenon Pharmaceuticals Inc. (the “Entity”) which comprise the consolidated balance sheet as of December 31, 2024, the related consolidated statements of operations and comprehensive loss, shareholders’ equity and cash flows for each of the years in the two-year period ended December 31, 2024, and the related notes (collectively the “consolidated financial statements”), which is included in the Annual Report on Form 10-K of the Entity for the fiscal year ended December 31, 2025.

We also consent to the incorporation by reference of such report in the Registration Statements (Nos. 333-279962, 333-265377, 333-238895, 333-237036, 333-233758, 333-230103, 333-223497, 333-216543, 333-210050, 333-202765, 333-199860, 333-291868, 333-285382) on Form S-8, and No. 333-281451 on Form S-3 of the Entity.

 

/s/ KPMG LLP

Chartered Professional Accountants

February 26, 2026
Vancouver, Canada

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer